von Tresckow, B. and Engert, A. (2014). Brentuximab vedotin. A new targeted approach for the treatment of relapsed or refractory Hodgkin's lymphoma patients. Onkologe, 20 (5). S. 464 - 470. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Full text not available from this repository.

Abstract

Brentuximab vedotin is a new antibody drug conjugate consisting of a monoclonal antibody which is specifically linked to a potent synthetic cytostatic drug. This construct is directed against the CD30 antigen that is highly expressed on the malignant cells of Hodgkin's lymphoma (HL) tumors. A systematic review of the current status of therapy of HL with brentuximab vedotin is presented. A systematic literature search was performed in Pubmed, MEDLINE, current guidelines and by manual searching. Relevant publications from the last 5 years were analyzed and the results are summarized in a structured review. Brentuximab vedotin has demonstrated high clinical activity in trials performed in intensively pretreated patients with HL showing an overall response rate (ORR) of 75 %. The most commonly observed side effects include moderate neutropenia and more rarely peripheral neuropathy. Brentuximab vedotin was registered by the European Medicines Agency (EMA) in October 2012 for the treatment of relapsed and refractory HL patients in Europe. With the approval of brentuximab vedotin a new standard of care for patients with relapsed or refractory HL has become available. Current clinical trials are evaluating brentuximab vedotin as a combination partner for conventional chemotherapy in first and second line treatment. Moreover, brentuximab vedotin has been used as bridging treatment before allogeneic stem cell transplantation in patients with multiple recurrences.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
von Tresckow, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Engert, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-439220
DOI: 10.1007/s00761-014-2652-z
Journal or Publication Title: Onkologe
Volume: 20
Number: 5
Page Range: S. 464 - 470
Date: 2014
Publisher: SPRINGER HEIDELBERG
Place of Publication: HEIDELBERG
ISSN: 1433-0415
Language: German
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
STERNBERG-REED CELLS; OLDER PATIENTS; INTENSITY; DISEASE; CHEMOTHERAPY; DIAGNOSIS; MOLECULE; POTENT; SGN-35; TRIALMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/43922

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item